Company Announcement: Simcere Pharma announced that its investigational new drug candidate, SIM0610, has received Clinical Trial Approval from the National Medical Products Administration of China.

Drug Purpose: SIM0610 is a Bispecific Antibody-Drug Conjugate (BsADC) intended for evaluation in patients with locally advanced or metastatic solid tumors.

Market Activity: The company's stock experienced a slight increase of 0.050 (+0.389%) with short selling amounting to $5.28 million and a ratio of 10.987%.

Stock Information: Note that the Hong Kong stock quote is delayed by at least 15 minutes, and the short selling data is as of December 23, 2025, at 16:25.

Licensing Agreement: SIMCERE PHARMA's subsidiary, Jiangsu Zaiming, has signed an exclusive licensing agreement with Ipsen Pharma SAS for the global rights to develop, manufacture, and commercialize the antibody-drug conjugate SIM0613 outside of Greater China.

Financial Terms: The agreement includes potential earnings of up to US$1.06 billion for SIMCERE PHARMA, consisting of a US$45 million upfront payment and additional milestone payments, along with tiered royalties on sales contingent on successful development and regulatory approvals.

Stock Performance: SIMCERE PHARMA (02096.HK) experienced a slight decline of 0.445% with a short selling amount of $9.32 million and a ratio of 11.904%.

New Drug Inclusion: ENZESHU (Suvemcitug for injection) has been officially added to the National Basic Medical Insurance Drugs Catalogue, effective January 1, 2026.

Renewal of Drug Listing: ENDOSTAR (Recombinant Human Endostatin for Injection) has successfully completed its renewal under the National Reimbursement Drug List (NRDL).

Market Information: The stock quote for HK stocks is delayed by at least 15 minutes, with short selling data as of December 5, 2025.

Stock Performance: Various stocks are listed with their current prices, short selling data, and investment ratings, indicating a mix of gains and losses across different companies.

Investment Ratings: Most stocks mentioned, including FORTUNE REIT, OMNIVISION, and Alibaba, are rated as "Buy," suggesting a positive outlook from analysts.

Stock Performance Overview: Several pharmaceutical stocks showed mixed performance, with HENGRUI PHARMA and HANSOH PHARMA experiencing gains, while CSPC PHARMA and KELUN PHARM saw slight declines.

Short Selling Data: Short selling activity was notable, particularly for CSPC PHARMA and SIMCERE PHARMA, with significant ratios indicating investor caution in these stocks.